Applications

Monoclonal Antibody (mAB)

Monoclonal antibodies (mAbs) represent a groundbreaking class of therapeutic agents, offering unparalleled specificity in targeting diseases, particularly in oncology, autoimmune-, and infectious diseases. The monoclonal antibody manufacturing process is a sophisticated sequence of biotechnological steps crucial for ensuring the high purity, efficacy, and safety of these biotherapeutics. Central to the mAb manufacturing process is the utilization of advanced bioreactors, with the Applikon single-use or multi-use bioreactors emerging as an essential tool for researchers and manufacturers aiming to streamline mAb production processes.

Optimizing Monoclonal Antibody Production with Applikon Bioreactors

The production of monoclonal antibodies (mAbs) involves a series of carefully coordinated steps, from selecting a specific antigen target to cultivating antibody-producing cells and purifying the final product. Let’s explore how Applikon’s single-use and multi-use bioreactors can optimize each stage of the mAbs manufacturing process, making it more efficient and beneficial for customers.

Selecting and Preparing the Bioreactor System and Antigen

The first and crucial step in how to make monoclonal antibodies involves choosing the most suitable equipment based on the product and the goals of the bioprocess. Options include batch, fed-batch, perfusion, or chemostat processes. Applikon bioreactors support all these process forms, ensuring maximum productivity and flexibility to meet various production needs. Identifying and preparing the specific antigen that the monoclonal antibody will target involves finding a unique marker associated with the disease. Optimizing antigen selection and preparation with Applikon allows for quick and accurate identification of markers, enhancing the accuracy and efficiency of the produced antibodies.

Generating and Selecting High-Performance Cells

Producing monoclonal antibodies primarily uses Chinese hamster ovary (CHO) cells as production organism.  Advanced biotechnological techniques such as transcriptomics, proteomics, and methotrexate-based amplification are used to enhance the expression of genetic factors and significantly increase the productivity of monoclonal Antibodies. CHO cells are extensively used in the biopharmaceutical industry due to their exceptional ability to perform complex post-translational modifications, which are crucial for the functional efficacy of therapeutic proteins. Although there are other production organisms, CHO cells are the preferred option for mAB production. The hybridoma technology, for example, which involves fusing B-cells that produce a specific antibody with myeloma cells, creates hybrid cells capable of continuous production. Although foundational in enabling the production of specific antibodies, the hybridoma method is less scalable compared to the production with CHO cells. The scalability and adaptability of CHO cells in large-scale manufacturing provides a more efficient and versatile platform for antibody production. This approach illustrates the steps to produce monoclonal antibodies effectively in modern biotechnological contexts, emphasizing scalability and precision.

Optimized Cell Expansion and Cultivation

Once the optimal cells are selected, expanding and cultivating them under ideal conditions is critical for high-quality mAb production with high yields. Applikon bioreactors provide precise control over temperature, pH, and dissolved oxygen levels, which are essential for maximizing cell growth and antibody yield. This optimized environment supports robust cell expansion and efficient antibody production, ensuring a consistent and reliable supply of mAbs.

Why Choose the Applikon AppliFlex ST Single-Use Bioreactor for mAb Manufacturing?

The Applikon AppliFles ST single-use bioreactor stands out in the monoclonal antibodies manufacturing landscape for several reasons:

  • Precision and control: It offers unique control over environmental conditions, ensuring optimal cell growth and productivity.
     
  • Scalability: Available in different volumes, it offers the scientist the opportunity to develop a process and subsequently scale it up to commercial-scale mAb production.
     
  • Efficiency: The AppliFlex ST allows you to dive straight into your bioprocess thanks to a quick setup and easy operation. This reduces production times and costs, enhancing the overall efficiency of the mAb manufacturing process.
     
  • Versatility: Thanks to customization options the AppliFlex ST bioreactor is a versatile tool for different mAb production processes, supporting a wide range of cell types and cultivation strategies.

Benefits of Using the Applikon Bioreactor

In conclusion, the monoclonal antibody production process represents a highlight of biotechnological innovation, with the Applikon AppliFles ST single-use bioreactor playing a critical role in enabling the efficient and scalable production and development of these vital therapeutic agents. As a leading monoclonal antibodies manufacturer, embracing the capabilities of the Applikon bioreactors can significantly enhance the efficiency, yield, and quality of mAb production, positioning manufacturers at the forefront of biopharmaceutical development. Discover how the Applikon AppliFlex ST single-use bioreactor can transform your mAb manufacturing process.

Feautured Products

We are eager to receive your feedback

* Mandatory fields